Citadel Advisors’s Elicio Therapeutics ELTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ELTX
KCM
Citadel Advisors's ELTX Position: Q3 2026 in Review
Citadel Advisors opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 543,450 shares worth $989K. The stake represents ﹤0.01% of the portfolio and ranks #8483 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELTX as recently as Q1 2026.
Citadel Advisors first reported a position in ELTX in Q1 2021 and has held it in 9 quarters since. 78 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.
- Citadel Advisors held 543,450 shares of Elicio Therapeutics worth $989K as of Q3 2026.
- Elicio Therapeutics was a new Citadel Advisors position in Q3 2026.
- Elicio Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #8483 holding.
- Citadel Advisors first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 9 quarters since.
- 78 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.